Artios Pharma welcomes experienced leader to chair its Board. Aims to make more value for investors by commercialisation of its cancer therapies

Artios Pharma has named US-based MBA, CA, CPA Pierre Legault as Chairman of its Board of Directors, to be effective immediately. Citing his leadership experience in the global biopharmaceutical industry, the company pointed out that he’s been leading companies through high phases of growth to deliver significant shareholder value.

Legault has experience as Chief Executive Officer of Prosidion Ltd., Chief Financial Officer of OSI Pharmaceuticals and he also served as President, Chief Executive Officer and Chief Financial Officer at various legacy companies of the Sanofi-Aventis group, Artios noted in its Monday press release.

Pierre Legault

He is currently serving as the Chairman of the Board of Poxel (France), and is a Director on the Boards of Syndax Pharmaceuticals (US), ARMO BioSciences (US) and Clementia Pharmaceuticals (US). Prior Board and executive positions include Forest Laboratories, Tobira Therapeutics, NPS Pharmaceuticals, Regado Biosciences, Iroko Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy and Nephrogenex, where he was Chairman and Chief Executive Officer.

Dr. Niall Martin, Chief Executive Officer of Artios Pharma, said Legault’s Board experience with his global network, will be hel’ Artios to position itself as a world leading DDR company. Martin has called for Legault’s experience in growing companies, developing them from early discovery stage through to commercialisation in multiple territories.

Pierre Legault, now Chairman of the Board of Directors at Artios Pharma, said he’s looking forward to work with Artios’ highly innovative pipeline towards the clinic in a growing market for DDR targeted therapies. “I welcome the opportunity to work with an outstanding management team, which is supported by a strong Board and investor syndicate, to bring novel breakthrough DDR targeted therapies to cancer patients, while also creating value for investors.”,” he said.